Deep Value: cash covers about 94% of the stock price

This company holds roughly $43M in cash and investments — about 94% of its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Context Therapeutics

CNTX

Biotechnology · Healthcare

Price

$0.50

-0.02 (-3.77%)

Market Cap

$45.9M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+3258.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 2.8M (2021) → 95.2M (2025)

Winston Score History

The full picture

Context Therapeutics is a small clinical-stage biotech company focused on developing drugs to treat cancer, particularly in women. Its main programs target breast cancer and other solid tumors using experimental therapies that block proteins helping cancer cells grow. The company does not yet sell any approved products and is working to advance its drug candidates through clinical trials.

Context Therapeutics does not currently generate meaningful revenue, which is typical for early-stage biotechs. It funds its research primarily through stock offerings and other financing, and it operates mainly in the United States. The company's negative ROIC reflects heavy spending on trials with no commercial income yet. The key risk is that its drug candidates may fail in clinical testing or face difficulty raising the additional capital needed to reach approval — a common and serious challenge for small biotechs with no approved products on the market.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-61.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$32M/ year

↑ Rising (+40% vs prior year)

R&D investment increasing — building for the future

Insider Activity

29.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~18 months

$43M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-126.8%

Weak — -126.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.01

Conservative — low debt load (0.01)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial